[{"data":1,"prerenderedAt":272},["ShallowReactive",2],{"story-5349-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":48,"questions":49,"relatedArticles":59,"body_color":270,"card_color":271},"5349",null,"Samsung Biologics Breaks Global Pharma Manufacturing Boundaries with Strategic US Expansion","- Transforming international pharmaceutical supply chains through targeted cross-border manufacturing investments",[],[10,11,12,13,14,15,16,17,18,19,20,21,15,22,23,24,25,26,26,26,27,26,17,28,29,26,30,31,32,23,33,34,35,36,37,38,39,40,26,41,42,43,44,45,46,47],"https://commercialobserver.com/wp-content/uploads/sites/3/2025/12/John-Rim-HGSI-Samsung-Biologics-campus-Rockville-Md-credit-Samsung-Biologics.jpg?quality=80&w=763&h=489&crop=1","https://cdn.techinasia.com/wp-content/uploads/2025/06/1750134121_headquarters_itm1-750x419.jpg","https://image.ajunews.com/content/image/2025/12/22/20251222094433938159.jpg","https://www.biospectrumasia.com/uploads/articles/screenshot_22_12_2025_12138_www_prnewswire_com-27025.jpeg","https://www.koreabiomed.com/news/photo/202512/30050_32264_1016.jpg","https://cdn.zonebourse.com/static/resize/0/0//images/reuters/2025-04/2025-04-30T061040Z_1_LYNXMPEL3T07L_RTROPTP_4_GSK-RESULTS.JPG","https://koreajoongangdaily.joins.com/data/photo/2025/12/22/3da1e453-007e-4471-ae2a-0dd56ae6b89f.jpg","https://www.chosun.com/resizer/v2/MVTDMMTCGA4TOOJYGVRGKNJVHE.jpg?auth=c53c397423e1368d2bd9599b10640d6ff7e5b7ed0e9843acf424a64ebd6a715c&width=616","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2024-10-09T081107Z_1_LYNXMPEK98083_RTROPTP_3_GERMANY.JPG","https://wimg.mk.co.kr/news/cms/202512/23/20251223_01110105000003_M00.jpg","https://www.globalbankingandfinance.com/_next/image/?url=https%3A%2F%2Fimagedelivery.net%2FMkQ8HKvpw9EqULcU_pSqWg%2Fcloud-bccb4c31-c889-45a7-ae13-69de0e2045aa%2Fpublic&w=3840&q=85&dpl=dpl_AW2uQ8ma8YWXu6MmDoKdviVr2XKJ","https://businessfacilities.com/wp-content/uploads/2025/12/samsung-biologics-gsk-md.jpg","https://newsimg.koreatimes.co.kr/2025/12/22/de376285-e78f-4d0b-9f63-c1bb9f1cbd57.jpg","https://wimg.heraldcorp.com/news/cms/2025/12/22/news-p.v1.20251222.ac0ef926fe1d4024bd06c43bf9aae125_P1.png","https://www.geneonline.com/wp-content/uploads/EN_Mobile_Dec_HIV_AIDS-450x350.png","https://bl-i.thgim.com/public/incoming/l6m6g2/article70424971.ece/alternates/LANDSCAPE_1200/f9c7e60d7c6e4e8e8507caae03a8eeef_thumb.jpg","https://mma.prnewswire.com/media/2850103/Image__Samsung_Biologics_Expands_U_S__Manufacturing_Capabilities.jpg","https://www.asiabusinessoutlook.com/uploaded_images/newstransfer/d7i01736220811_shutterstock_1668796654-scaled.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1SN2cq.img?w=768&h=512&m=6","https://www.azernews.az/media/2025/12/22/samsung_biologics.jpg","https://cdn.bisnow.net/fit?height=1200&type=png&url=https%3A%2F%2Fs3.amazonaws.com%2Fcdn.bisnow.net%2Fcontent%2Fimages%2F2025%2F12%2F69495ffa1d4ba-screenshot-2025-12-22-at-10-12-06-am.png&width=1200&sign=WbFuNxaEu_VAnVSDoyLPlGnrcmoBTZOIrtF9jbW4fbQ","https://wimg.mk.co.kr/news/cms/202512/22/news-p.v1.20251222.57dd4c90002044bd87368891bf9bcb2e_P1.jpg","https://etimg.etb2bimg.com/photo/126113611.cms","https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1200&q=100&f=webp&t=1","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2215021361.jpg?VersionId=UngKaoH_bkUnG.FBzEAB0.I9J9Tbdqj9","https://www.indianpharmapost.com/public/thumbs/news/2025/12/18647/Human_Genome_Sciences1.jpg","https://www.contractpharma.com/wp-content/uploads/sites/6/2025/12/human-genome-sciences.jpg","https://wimg.mk.co.kr/news/cms/202512/22/news-p.v1.20251222.439cb83c6cfa4c8cbd276b97b3b33b51_P1.jpg","https://unn.ua/_next/image?url=https%3A%2F%2Funn.ua%2Fimg%2F2025%2F12%2F22%2F1766362912-1073-large.webp&w=720&q=75","https://etimg.etb2bimg.com/thumb/msid-126112253,width-1200,height-900,resizemode-4/.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1SN8Zv.img?w=768&h=576&m=6","https://biz.chosun.com/resizer/v2/LNKJ7S73BFAHHGXFOUY34V7MVU.jpg?auth=a73c11558caf24315412a05b15d5e805285a246762d49095380da17e57b1a8f0&width=1200&height=630&smart=true","https://media.bizj.us/view/img/13113056/imagesamsungbiologicsexpandsusmanufacturingcapabilities*900xx2161-1218-0-0.jpg","http://koreabizwire.com/wp/wp-content/uploads/2025/01/AEN20250114002800320_01_i_org.jpg","https://www.reuters.com/resizer/v2/OPPP273TMJKEFBIK4LWZSRVDUA.jpg?auth=f3ee02bcc19483ffdf09c5351693428ccf1859c3e5360433c0d23a659c148aa9&width=1920&quality=80","https://m.economictimes.com/thumb/msid-126112281,width-1200,height-900,resizemode-4,imgsize-23350/samsung-biologics-to-invest-usd-4-8-billion-in-new-songdo-bio-campus.jpg","https://cdn.sanity.io/images/0vv8moc6/pharma_commerce/3a9baad4cf5d395b09197012b1369b904b38f795-1592x886.png?w=1592&max-h=886&fit=crop&auto=format","https://images.ft.com/v3/image/raw/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F8%2F2%2F8%2F11858283-2-eng-GB%2Fa9ad3878cab7-2025-12-17T000129Z_372490497_RC2AYCAK1RN4_RTRMADP_3_HEALTH-USA-GSK-2-.JPG?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto","**Samsung Biologics** is rewriting the playbook for international pharmaceutical manufacturing through a bold $280 million strategic acquisition that transforms its global production capabilities. By purchasing GSK's Rockville, Maryland facility, the company is executing a sophisticated market entry strategy that goes far beyond simple asset acquisition.\n\nThe acquisition represents more than a transaction—it's a calculated geopolitical and economic maneuver. **Samsung Biologics** is establishing a dual-hemisphere production system connecting Songdo, Korea, and Rockville, USA, which strategically mitigates regional supply chain risks while providing North American customers with local manufacturing options. This move is particularly shrewd given the current landscape of pharmaceutical localization and potential trade policy shifts.\n\nThe **60,000-liter drug production facility** comes with a critical advantage: 500 existing workers who ensure immediate production continuity and deep institutional knowledge transfer. By retaining the entire workforce, Samsung Biologics demonstrates a nuanced understanding that successful international expansion isn't just about infrastructure, but about human capital and expertise.\n\nCritically, this investment aligns with broader U.S. policy trends emphasizing domestic pharmaceutical manufacturing. Under existing trade agreements, tariffs on U.S. imports of South Korean pharmaceuticals are capped at 15%, with generic drugs receiving tariff-free treatment—creating a favorable environment for this strategic move. The company's current South Korean capacity of 785,000 liters across five plants positions this U.S. facility as a complementary, not redundant, expansion.\n\nThe acquisition signals a sophisticated approach to global market positioning. Samsung Biologics isn't just buying a facility; it's establishing a beachhead in the competitive U.S. pharmaceutical manufacturing landscape. By investing in existing infrastructure, the company can rapidly scale capabilities without the time-consuming process of building from scratch.\n\nFor pharmaceutical companies and investors, this represents a masterclass in strategic international expansion—leveraging existing assets, maintaining workforce continuity, and positioning for future market dynamics.",[50,53,56],{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"Why is Samsung Biologics investing $280 million in a US manufacturing facility?","Samsung Biologics is strategically expanding its global manufacturing footprint by establishing a US production base. This move allows them to mitigate supply chain risks, provide local manufacturing options for North American customers, and potentially benefit from US policies supporting domestic pharmaceutical production.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What competitive advantages does this acquisition provide Samsung Biologics?","The acquisition provides multiple advantages: immediate 60,000-liter production capacity, retention of 500 experienced workers, potential tariff benefits, and a strategic location in a key biotech cluster. It also allows rapid market entry without building a facility from scratch.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"How does this acquisition fit into Samsung Biologics' broader global strategy?","This represents a key part of Samsung Biologics' global expansion strategy, creating a dual-hemisphere production system connecting Korea and the US. It demonstrates the company's commitment to becoming a major international contract manufacturing organization (CMO) with flexible, high-quality pharmaceutical production capabilities.",[60,65,70,74,78,82,86,90,94,98,101,105,109,112,116,120,123,127,131,135,138,141,145,148,152,156,160,163,167,171,175,179,183,187,190,194,198,201,204,207,211,215,219,223,227,231,234,238,242,245,249,252,256,259,262,266],{"id":61,"title":62,"source":63,"logo":44,"time":64},129682,"Samsung Biologics to buy US drug production facility from GSK for $280 million","https://www.reuters.com/business/healthcare-pharmaceuticals/samsung-biologics-buy-us-drug-production-facility-gsk-280-mln-2025-12-21/","3D AGO",{"id":66,"title":67,"source":68,"logo":30,"time":69},132212,"Samsung Biologics To Pay $280M For Maryland Manufacturing Campus","https://www.bisnow.com/washington-dc/news/life-sciences/samsung-biologics-pays-280m-for-montgomery-county-manufacturing-campus-132479","2D AGO",{"id":71,"title":72,"source":73,"logo":31,"time":64},129683,"Samsung Biologics has taken over the U.S. biopharmaceutical production facility of global pharmaceut..","https://www.mk.co.kr/en/it/11497617",{"id":75,"title":76,"source":77,"logo":46,"time":69},132211,"Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition","https://www.pharmaceuticalcommerce.com/view/samsung-biologics-enters-us-manufacturing-market-gsk-site-acquisition",{"id":79,"title":80,"source":81,"logo":5,"time":64},129684,"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK","https://www.prnewswire.com/news-releases/samsung-biologics-expands-us-manufacturing-capabilities-with-strategic-acquisition-of-human-genome-sciences-from-gsk-302647637.html",{"id":83,"title":84,"source":85,"logo":10,"time":69},132210,"Samsung Biologics to Acquire First U.S. Drug Manufacturing Facility in $280M Deal","https://commercialobserver.com/2025/12/samsung-biologics-maryland-life-sciences/",{"id":87,"title":88,"source":89,"logo":14,"time":64},129600,"Samsung Biologics secures 1st US manufacturing base with GSK facility acquisition","https://www.koreabiomed.com/news/articleView.html?idxno=30050",{"id":91,"title":92,"source":93,"logo":35,"time":64},132214,"Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million","https://www.indianpharmapost.com/biopharma/samsung-biologics-strengthens-us-presence-with-acquisition-of-gsks-human-genome-sciences-or-280-million-18647",{"id":95,"title":96,"source":97,"logo":17,"time":64},129601,"Samsung Biologics Acquires GSK's U.S. Facility, First Production Base","https://www.chosun.com/english/industry-en/2025/12/22/KQ3YOEEQLZB27KW46B4EYRILDA/",{"id":99,"title":62,"source":100,"logo":33,"time":69},132213,"https://www.manilatimes.net/2025/12/23/business/foreign-business/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/2248220",{"id":102,"title":103,"source":104,"logo":22,"time":64},129681,"Samsung Biologics takes over bio plant in Maryland from GSK","https://www.koreatimes.co.kr/business/tech-science/20251222/samsung-biologics-takes-over-bio-plant-in-maryland-from-gsk",{"id":106,"title":107,"source":108,"logo":11,"time":64},129594,"Samsung Biologics to buy US drug plant from GSK for $280m","https://www.techinasia.com/news/samsung-biologics-buy-us-drug-plant-gsk-280m",{"id":110,"title":62,"source":111,"logo":45,"time":64},129595,"https://m.economictimes.com/news/international/business/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/articleshow/126112276.cms",{"id":113,"title":114,"source":115,"logo":39,"time":64},129596,"Samsung Biologics to buy its first US drug production facility from GSK for $280 million","https://pharma.economictimes.indiatimes.com/news/pharma-industry/samsung-biologics-to-buy-its-first-us-drug-production-facility-from-gsk-for-280-million/126112253",{"id":117,"title":118,"source":119,"logo":5,"time":64},129597,"Samsung Biologics acquires Human Genome Sciences from GSK","https://www.tipranks.com/news/the-fly/samsung-biologics-acquires-human-genome-sciences-from-gsk-thefly",{"id":121,"title":80,"source":122,"logo":26,"time":64},129598,"https://themalaysianreserve.com/2025/12/22/samsung-biologics-expands-u-s-manufacturing-capabilities-with-strategic-acquisition-of-human-genome-sciences-from-gsk/",{"id":124,"title":125,"source":126,"logo":26,"time":64},129599,"Samsung Biologics Expands U.S. Manufacturing Capabilities with S","https://www.gurufocus.com/news/4079138/samsung-biologics-expands-us-manufacturing-capabilities-with-strategic-acquisition-of-human-genome-sciences-from-gsk",{"id":128,"title":129,"source":130,"logo":43,"time":64},129590,"Samsung Biologics to Buy GSK Manufacturing Facility in U.S. for $280 Million","http://koreabizwire.com/samsung-biologics-to-buy-gsk-manufacturing-facility-in-u-s-for-280-million/340629",{"id":132,"title":133,"source":134,"logo":27,"time":64},129591,"Samsung Biologics to Acquire GSK's Maryland Plant for $280M","https://www.asiabusinessoutlook.com/news/samsung-biologics-to-acquire-gsk-s-maryland-plant-for-280m-nwid-10922.html",{"id":136,"title":62,"source":137,"logo":32,"time":64},129592,"https://manufacturing.economictimes.indiatimes.com/news/life-sciences/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/126113585",{"id":139,"title":62,"source":140,"logo":40,"time":64},129593,"https://www.msn.com/en-in/money/topstories/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/ar-AA1SNhV3?ocid=finance-verthp-feeds",{"id":142,"title":143,"source":144,"logo":34,"time":64},130809,"Samsung Biologics pays GSK $280M to secure first US manufacturing site","https://www.fiercepharma.com/manufacturing/samsung-biologics-pays-gsk-280m-secure-first-us-manufacturing-site",{"id":146,"title":114,"source":147,"logo":20,"time":64},129583,"https://www.globalbankingandfinance.com/samsung-biologics-usa/",{"id":149,"title":150,"source":151,"logo":23,"time":64},129584,"Samsung Biologics acquires $280m GSK plant, securing first US manufacturing base","https://www.theinvestor.co.kr/article/10641706",{"id":153,"title":154,"source":155,"logo":5,"time":64},129585,"Samsung Biologics Stock: Slips Nearly 5% After $280M GSK Maryland Plant Acquisition","https://coincentral.com/samsung-biologics-stock-slips-nearly-5-after-280m-gsk-maryland-plant-acquisition/",{"id":157,"title":158,"source":159,"logo":13,"time":64},129586,"Korea's Samsung Biologics expands US manufacturing capabilities after acquiring Human Genome Sciences from GSK","https://www.biospectrumasia.com/news/28/27025/koreas-samsung-biologics-expands-us-manufacturing-capabilities-after-acquiring-human-genome-sciences-from-gsk.html",{"id":161,"title":62,"source":162,"logo":25,"time":64},129587,"https://www.thehindubusinessline.com/companies/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/article70424941.ece",{"id":164,"title":165,"source":166,"logo":5,"time":64},129588,"Samsung Biologics Unit to Acquire GSK's Human Genome Sciences Facility in US for $280 Million","https://www.marketscreener.com/news/samsung-biologics-unit-to-acquire-gsk-s-human-genome-sciences-facility-in-us-for-280-million-ce7d50d2da8cfe24",{"id":168,"title":169,"source":170,"logo":16,"time":64},129589,"Samsung Biologics to acquire U.S. drug manufacturing facility from GSK","https://koreajoongangdaily.joins.com/news/2025-12-22/business/industry/Samsung-Biologics-to-acquire-US-drug-manufacturing-facility-from-GSK/2483446",{"id":172,"title":173,"source":174,"logo":5,"time":64},130778,"GSK to Sell US Manufacturing Site to Samsung Biologics for $280 Million","https://www.marketscreener.com/news/gsk-to-sell-us-manufacturing-site-to-samsung-biologics-for-280-million-ce7d50d2df8ef62c",{"id":176,"title":177,"source":178,"logo":37,"time":64},130779,"Samsung Biologics has secured a production base in North America by acquiring the U.S. biopharmaceut..","https://www.mk.co.kr/en/it/11504576",{"id":180,"title":181,"source":182,"logo":38,"time":64},129580,"Samsung Biologics acquires its first US plant for $280 million","https://unn.ua/en/news/samsung-biologics-acquires-its-first-us-plant-for-dollar280-million",{"id":184,"title":185,"source":186,"logo":18,"time":64},129581,"GSK to Sell Human Genome Sciences Unit to Samsung Biologics for $280 Million","https://www.marketscreener.com/news/gsk-to-sell-human-genome-sciences-unit-to-samsung-biologics-for-280-million-ce7d50d2df88fe27",{"id":188,"title":177,"source":189,"logo":19,"time":64},129582,"https://www.mk.co.kr/en/it/11504495",{"id":191,"title":192,"source":193,"logo":29,"time":69},130781,"Samsung Biologics to acquire GSK’s US plant","https://www.azernews.az/region/251990.html",{"id":195,"title":196,"source":197,"logo":17,"time":69},130782,"Samsung Biologics Acquires GlaxoSmithKline's U.S. Biopharmaceutical Facility","https://www.chosun.com/english/industry-en/2025/12/23/NSIRQV3NKZAE3IRMSPVDUDHFYE/",{"id":199,"title":150,"source":200,"logo":23,"time":64},130780,"https://www.koreaherald.com/article/10641494",{"id":202,"title":62,"source":203,"logo":5,"time":64},130785,"https://www.pharmalive.com/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/",{"id":205,"title":62,"source":206,"logo":15,"time":64},130786,"https://www.marketscreener.com/news/samsung-biologics-to-buy-its-first-us-drug-production-facility-from-gsk-for-280-million-ce7d50d2db8df322",{"id":208,"title":209,"source":210,"logo":12,"time":64},129578,"Samsung Biologics acquires GSK biopharmaceutical plant in U.S. for $280 million","https://www.ajupress.com/view/20251222093600641",{"id":212,"title":213,"source":214,"logo":47,"time":64},130783,"Samsung Biologics to buy GSK drug plant in US for $280m","https://asia.nikkei.com/business/business-deals/samsung-biologics-to-buy-gsk-drug-plant-in-us-for-280m",{"id":216,"title":217,"source":218,"logo":5,"time":64},129579,"Samsung Biologics acquires first U.S.-based manufacturing facility","https://en.yna.co.kr/view/AEN20251222002500320",{"id":220,"title":221,"source":222,"logo":36,"time":64},130784,"Samsung Biologics Acquires Human Genome Sciences from GSK","https://www.contractpharma.com/breaking-news/samsung-biologics-acquires-human-genome-sciences-from-gsk/",{"id":224,"title":225,"source":226,"logo":24,"time":69},132209,"Samsung Biologics Acquires $280 Million Manufacturing Facility in Maryland from GSK","https://www.geneonline.com/samsung-biologics-acquires-280-million-manufacturing-facility-in-maryland-from-gsk/",{"id":228,"title":229,"source":230,"logo":21,"time":69},132208,"Samsung Biologics Pays $280M For U.S. Drug Manufacturing Facility| Biotech","https://businessfacilities.com/samsung-biologics-pays-280m-maryland-drug-manufacturing-facility",{"id":232,"title":80,"source":233,"logo":26,"time":64},130787,"https://www.streetinsider.com/PRNewswire/Samsung+Biologics+Expands+U.S.+Manufacturing+Capabilities+with+Strategic+Acquisition+of+Human+Genome+Sciences+from+GSK/25766508.html",{"id":235,"title":236,"source":237,"logo":5,"time":69},132207,"News | Samsung Biologics to acquire facility outside DC for first US manufacturing plant","https://www.costar.com/article/2043707008/samsung-biologics-to-acquire-facility-outside-dc-for-first-us-manufacturing-plant",{"id":239,"title":240,"source":241,"logo":41,"time":64},129602,"Samsung Biologics acquires Rockville plant to secure US manufacturing base - CHOSUNBIZ","https://biz.chosun.com/en/en-science/2025/12/22/ORU4DPSYPBB37DX7RANLGIRT3A/",{"id":243,"title":62,"source":244,"logo":28,"time":64},129603,"https://www.msn.com/en-us/money/companies/samsung-biologics-to-buy-us-drug-production-facility-from-gsk-for-280-million/ar-AA1SMM0P?ocid=finance-verthp-feeds",{"id":246,"title":247,"source":248,"logo":15,"time":64},129604,"Samsung Biologics to buy U.S. drug production facility from GSK for $280 million","https://www.marketscreener.com/news/samsung-biologics-to-buy-u-s-drug-production-facility-from-gsk-for-280-mln-ce7d50d2db8df722",{"id":250,"title":80,"source":251,"logo":26,"time":64},129605,"https://www.lelezard.com/en/news-22060311.html",{"id":253,"title":254,"source":255,"logo":5,"time":64},129606,"Samsung Biologics snaps up Maryland drug plant, its first in the US","https://www.stocktitan.net/news/GSK/samsung-biologics-expands-u-s-manufacturing-capabilities-with-58iknggvxlzv.html",{"id":257,"title":80,"source":258,"logo":26,"time":64},129607,"https://www.barchart.com/story/news/36736421/samsung-biologics-expands-u-s-manufacturing-capabilities-with-strategic-acquisition-of-human-genome-sciences-from-gsk",{"id":260,"title":80,"source":261,"logo":5,"time":64},129608,"https://finance.yahoo.com/news/samsung-biologics-expands-u-manufacturing-224300355.html",{"id":263,"title":264,"source":265,"logo":26,"time":64},129609,"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK – Company Announcement - FT.com","https://markets.ft.com/data/announce/detail?dockey=600-202512211743PR_NEWS_USPRX____CN52272-1",{"id":267,"title":268,"source":269,"logo":42,"time":64},132370,"Samsung Biologics to acquire GSK's Rockville campus for $280M in first US manufacturing move","https://www.bizjournals.com/washington/news/2025/12/22/samsung-biologics-gsk-acquisition-rockville.html","#edaa57ff","#edaa574d",1766645441959]